FUS

Breakthrough in Treating Alzheimer's Using Targeted Drug Delivery Reported in New England Journal of Medicine

Retrieved on: 
Wednesday, January 3, 2024
Health, Family, Neurology, Consumer, Pharmaceutical, University, Mental Health, Research, Managed Care, Education, General Health, Science, Seniors, Clinical Trials, Traffic barrier, RNI, FUS, Male, Female, BBB, Blood, Insightec, PET, Donanemab, Ageing, Brain, Clinical trial, Patient, Safety, Therapy, Medical imaging

Anti-amyloid-beta (Aβ) monoclonal antibody therapies, such as aduncaumab, lecanemab, and donanemab, can reduce amyloid-beta plaques and slow the progression of Alzheimer’s.

Key Points: 
  • Anti-amyloid-beta (Aβ) monoclonal antibody therapies, such as aduncaumab, lecanemab, and donanemab, can reduce amyloid-beta plaques and slow the progression of Alzheimer’s.
  • More than 98 percent of drugs do not readily cross the BBB, thus requiring systemic treatments with higher doses and more frequent therapies.
  • The FUS MRI-guided treatment helmet with more than 1,000 ultrasound transducers were directed to specific brain regions with high amyloid-beta plaques.
  • “We are hopeful that the work we are doing may lead to improvements in outcome for many other patients and their families coping with Alzheimer’s.”

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Retrieved on: 
Wednesday, December 20, 2023
PROMIS, ALS, MSA, Neuroscience, Multiple system atrophy, Cytoplasm, FUS, Frontotemporal lobar degeneration, Disease, RACK1, PMN, TAR, Activated, FTLD, Cell, Therapy, Neuron

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a publication identifying Receptor for Activated C-Kinase 1 (RACK1) as a novel misfolded protein target for ALS and frontotemporal lobar degeneration (FTLD). The article published in the online edition of Acta Neuropathologica Communications is titled, "Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration."

Key Points: 
  • The article published in the online edition of Acta Neuropathologica Communications is titled, "Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration."
  • Under normal conditions, TDP-43 and FUS are predominantly localized in the nucleus of cells, where they participate in the regulation of protein expression.
  • In disease, however, they typically become mislocalized in the cytoplasm of neurons where they form aggregates.
  • The study authors reported that pathological FUS and TDP-43 both co-aggregate with RACK1 resulting in suppression of protein synthesis.

INSIGHTEC NAMED BIOFLORIDA COMPANY OF THE YEAR

Retrieved on: 
Monday, October 16, 2023
Partnership, Permeability, Conference, Essential tremor, Movement disorder, Bioceramic, Health, RTI, The Advisory Board Company, FDA, Insightec, OPKO Health, Growth, Ology, Tremor, Blood–brain barrier, NEXT Woman of the Year awards, Research, Catalyst Pharmaceuticals, MRI, Axogen, Parkinson's disease, Liquid biopsy, Prostate, Brain, FUS, Patient, Quality of life, Medical imaging, Pharmaceutical industry

MIAMI, Oct. 16, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has been awarded the 2023 BioFlorida David J. Gury Company of the Year Award for distinguished achievement in focused ultrasound technology and contributions to Florida's life sciences industry. The award was presented at BioFlorida's 26th Annual Conference in Ponte Verdra Beach to an audience of statewide leaders in Florida's life sciences industry.

Key Points: 
  • MIAMI, Oct. 16, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has been awarded the 2023 BioFlorida David J. Gury Company of the Year Award for distinguished achievement in focused ultrasound technology and contributions to Florida's life sciences industry.
  • The David J. Gury Company of the Year Award, named for one of the founding directors of BioFlorida, honors a company that has significant company achievements with measurable results including financing deals, partnering agreements, research discoveries, grants, clinical trials, approvals, product development and commercialization milestones.
  • Recipients must also be BioFlorida members who demonstrate a history of service to BioFlorida and its mission - to advance the life sciences industry in Florida.
  • Insightec is also exploring other treatment applications in the body, such as prostate disease.

How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression

Retrieved on: 
Wednesday, August 2, 2023
FUS, AB, Quality of life, ALS, Hope, Launch, Neurology, Attitude, Market, Patient, Sodium phenylbutyrate/ursodoxicoltaurine, Ursodoxicoltaurine, FDA, Disease, Pharmaceutical industry, Medical device

Amylyx’s Relyvrio™ (sodium phenylbutyrate and taurursodiol) launched 10 months ago, and Ionis/Biogen’s Qalsody™ (tofersen) was just approved in 2023.

Key Points: 
  • Amylyx’s Relyvrio™ (sodium phenylbutyrate and taurursodiol) launched 10 months ago, and Ionis/Biogen’s Qalsody™ (tofersen) was just approved in 2023.
  • Consistent with that attitude, neurologists in the study acknowledge a very high unmet need for new ALS treatments – saying they seek truly disease-modifying treatments.
  • The Market Dynamix™: ALS study also asked neurologists what they would deem to be a meaningful therapeutic development in a new therapy.
  • Spherix monitors the quarterly changes in the ALS treatment market through its Launch Dynamix™: Relyvrio tracking study.

Focused Ultrasound Treatment is Proven an Effective Treatment to Curb Tremor for at Least Five Years

Retrieved on: 
Thursday, July 20, 2023
Essential tremor, Tremor, Life, International Classification of Functioning, Disability and Health, FUS, Medicine, Clinical trial, Quality of life, CRST, Trial of the century, High-intensity focused ultrasound, ET, MD, Patient, The New England Journal of Medicine, FDA, Health, Journal of Neurosurgery, Safety, QUEST, Pharmaceutical industry, Medical imaging, Insightec, Neurosurgery

HAIFA, Israel and MIAMI, July 20, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using focused ultrasound (FUS) technology to transform patient care, today announced FDA approval of the five-year study endpoint for the largest prospective long-term, follow-up study of unilateral MR-guided focused ultrasound (MRgFUS) surgery (thalamotomy) for essential tremor (ET) to date. The data shows sustained and significant tremor improvement at five years with an overall improvement in quality-of-life measures and without any progressive or delayed complications. The study also confirms the long-term efficacy of the procedure for sufferers of ET, and follows the recent FDA approval of use of the technology to treat the second side tremor of appropriate patients. Insightec's Focused Ultrasound technology has been used to perform over 11,000 procedures worldwide.

Key Points: 
  • Insightec's Focused Ultrasound technology has been used to perform over 11,000 procedures worldwide.
  • "It also substantiates that using MR-guided focused ultrasound to treat essential tremor is safe and effective, as well as long-lasting.
  • We look forward to making further progress in finding more uses for focused ultrasound and building on the success of the treatment of essential tremor."
  • "Being part of the clinical study 7 years ago was life changing," says Alexandra Lebenthal, a clinical trial Focused Ultrasound patient from 2016.

Non-invasive ultrasound stimulation of the spleen reduces inflammation in humans, new results from a clinical trial

Retrieved on: 
Monday, April 24, 2023
Research, Hospitals, Diabetes, Other Health, Radiology, Managed Care, Health, Science, Oncology, Infection, Human, Obesity, TNF, FUS, Feinstein Institutes for Medical Research, Vagus nerve, Arthritis, Inflammatory Bowel Diseases, Cancer, GE, DRS, Multimedia, Inflammation, Biomedical engineering, Doctor of Philosophy, MS, Neuroscience, Bioelectronics, Spleen, Patient, GE Research, Blood, Feinstein, Pulmonary hypertension, Credit, Molecular medicine, Medical research, Disease, Medical imaging, Medical device, Vaccine, MD

Results from human studies published in the journal Brain Stimulation point to the possibility of using bioelectronic medicine and neuromodulation to treat inflammatory diseases traditionally treated only with drugs.

Key Points: 
  • Results from human studies published in the journal Brain Stimulation point to the possibility of using bioelectronic medicine and neuromodulation to treat inflammatory diseases traditionally treated only with drugs.
  • Sangeeta Chavan (left) and Stavros Zanos (right) helped lead the new study which published in the journal Brain Stimulation.
  • In 2021, the Feinstein Institutes and GE Research team showed the anti-inflammatory effects of liver-focused ultrasound on obesity in preclinical models.
  • Chavan and Zanos, along with GE Research and other collaborators, showed the ability of ultrasound to reverse diabetes in preclinical studies.

Insightec Announces Milestone of First Patients Enrolled in the Pivotal LIBERATE Clinical Trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors)

Retrieved on: 
Thursday, December 15, 2022
FUS, Glioblastoma, MD, Baptist Health, Liquid biopsy, Alzheimer's disease, Disease, Diagnosis, MRI, Partnership, Research, Sunnybrook Health Sciences Centre, Health, Patient, Biomarker, Opioid, Mayo Clinic, Biopsy, Neuropsychiatry, BBB, Tremor, DNA, Epilepsy, Neuro, Neurosurgery, Essential tremor, Baptist Health South Florida, FDA, Brain, Cancer, Nucleic acid thermodynamics, Circulating tumor DNA, Permeability, Safety, Parkinson's disease, Burns, Neoplasm, MIAMI, Principal, DRS, MBA, Risk, Medical imaging, Pharmaceutical industry, Insightec

HAIFA, Israel & MIAMI, Dec. 15, 2022 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced today the first patients have enrolled in the pivotal LIBERATE clinical trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors). Enrollment in LIBERATE marks the start of an international effort to assess safety and efficacy of using Insightec's focused ultrasound (FUS) platform to temporarily disrupt the blood brain barrier (BBB) to enable liquid biopsies in patients with glioblastoma, the most common primary malignant brain tumor in adults.

Key Points: 
  • HAIFA, Israel & MIAMI, Dec. 15, 2022 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced today the first patients have enrolled in the pivotal LIBERATE clinical trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors).
  • "Our team at Mayo Clinic is excited to have enrolled the first patient in this pivotal trial," said neurosurgeon Terry Burns MD PhD.
  • Importantly, FUS can be repeated non-invasively, allowing a rare molecular window into individual patient's brain tumors as they evolve during treatment."
  • "Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether standing alone or in connection with the word "Insightec", are protected trademarks of Insightec.

Unique human neuromuscular junction assay establishes skeletal muscle as a key player in ALS

Retrieved on: 
Tuesday, October 18, 2022
Stem Cells, Biotechnology, Technology, Health, Pharmaceutical, Medical Devices, Research, Nanotechnology, Genetics, Science, Hardware, Movement, Therapy, Amyotrophic lateral sclerosis, Diagnosis, B cell, MPS, NMJ, Research, HIV disease progression rates, Cell, FUS, ALS, SOD1, Neuromuscular junction, Death, Gene, Medical imaging, Biomaterial

This study used human induced pluripotent stem cells in a microphysiological system (MPS) that compared wild type (healthy) cells against patient derived mutant (diseased) cells.

Key Points: 
  • This study used human induced pluripotent stem cells in a microphysiological system (MPS) that compared wild type (healthy) cells against patient derived mutant (diseased) cells.
  • Specifically, the team looked at the relative contributions of diseased skeletal muscle and motoneurons on disease pathophysiology.
  • While the root cause of ALS still remains unresolved, the study produced findings that suggest diseased skeletal muscle plays a significant role in NMJ signal disruption, independent of motoneurons.
  • The neuromuscular junction is the point where motoneurons connect with skeletal muscle and is responsible for transmitting signals that dictate movement.

Global High Intensity Focused Ultrasound Market (2022 to 2027) - Featuring Hitachi, General Electric and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 16, 2022
Medical Devices, Health, FDA, Pancreas, Liver, Woman, BPH, High-intensity focused ultrasound, Johnson & Johnson, Cancer, Industry, R, Breast, Prostate cancer, Growth, EDAP, Prevalence, Tissue, Research, International Prostate Symptom Score, Blood, FUS, Lymph, Man, Medtronic, COVID-19, Prostate, Urinary bladder, Lists of diseases, Hemostasis, Safety, Awareness, Kidney, Cavitation, Clinic, Aesthetics, General Electric, Heat, LUTS, Hitachi, American Institute for Cancer Research, Disease, Medical imaging, Pharmaceutical industry, HIFU

Besides, focused ultrasound surgery (FUS) is a non-invasive technique that can ablate tumor lesions precisely when combined with high-intensity imaging methods.

Key Points: 
  • Besides, focused ultrasound surgery (FUS) is a non-invasive technique that can ablate tumor lesions precisely when combined with high-intensity imaging methods.
  • As the COVID-19 pandemic progresses, the High-intensity focused ultrasound (HIFU) therapy industry has seen a growth drop.
  • Worldwide High-intensity Focused Ultrasound (HIFU) Therapy Market Size was US$ 269.3 Million in 2021:
    Based on modality, the High-Intensity Focused Ultrasound Therapy market is segmented into therapeutic ultrasound, hemostasis, others.
  • Major players operating in the HIFU therapy industry include Johnson & Johnson, Hitachi, Ltd, General Electric, Medtronic, Inc., Stryker, Koninklijke Philips, EDAP TMS S.A, Supersonic Imagine.

Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment

Retrieved on: 
Monday, June 13, 2022
Mental Health, Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, FTD, Alzheimer's disease, OTC Markets Group, Company, Cognition, Survival, ACOG, Toxicity, Amyotrophic lateral sclerosis, Central nervous system, Forward-looking statement, FUS, Pathology, Neurodegeneration, ALPHA, News, Disease, Inflammation, Rivastigmine, Failure, Motor neuron, Therapy, Growth hacking, Memantine, FDA, Growth, Patient, Advertising, Gemstone, Technology, ALS, COVID-19, TSX, ACI, Industry, Cathepsin D, GEM, Granulin, Donepezil, TSX Venture Exchange, SMA, Terminology, Pharmaceutical industry, Frankincense, Aroma compound, Dietary supplement

ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from full length progranulin (PGRN) which have therapeutic potential across multiple neurodegenerative diseases.

Key Points: 
  • ALPHA-0702 and ALPHA-0802 are Granulin Epithelin Motifs, or GEMs, derived from full length progranulin (PGRN) which have therapeutic potential across multiple neurodegenerative diseases.
  • These data underscore robust preclinical evidence supporting Alpha Cognitions approach to treating neurodegenerative disease and highlight the Companys strategy to validate these data in additional pre-clinical studies.
  • These benefits have been observed in preclinical studies and strongly support the continued development of both compounds for the treatment of neurodegenerative diseases.
  • This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.